Lexaria Bioscience Receives Nasdaq Delisting Notice After Reverse Split

What Happened
Lexaria Bioscience Corp. (LEXX) filed an 8‑K saying it received a notification from the Nasdaq Capital Market on August 4, 2026 that it would be delisted for failing to regain compliance with Nasdaq Listing Rule 5550(a)(2) (the $1.00 minimum bid requirement) within the 180‑day compliance period under Rule 5810(c)(3)(A). The company completed a reverse stock split on August 3, 2026 (announced July 30, 2026) and its shares have been trading under CUSIP 52886N604 with a current minimum bid above $1.00. Lexaria filed and paid for a hearing request to suspend the delisting while it seeks to regain and sustain compliance.

Key Details

• Nasdaq notification date: August 4, 2026.
• Relevant rule: Nasdaq Listing Rule 5550(a)(2) — $1.00 minimum bid price; 180‑day compliance period under Rule 5810(c)(3)(A).
• Reverse stock split completed: August 3, 2026; trading under CUSIP 52886N604.
• Company has requested a hearing and paid the fee to stay delisting; it expects to regain compliance before any hearing and to remain trading on Nasdaq without interruption.

Why It Matters
A delisting determination signals regulatory noncompliance that could lead to removal from Nasdaq if not cured, which can reduce liquidity and investor access. Lexaria has taken corrective action (reverse split) and has formally asked for a hearing to pause delisting proceedings while it meets the $1.00 bid requirement; investors should monitor trading, company updates, and Nasdaq communications for confirmation of regained compliance or further developments.